Evaluation of efficacy and safety of Collashot C2 plus capsule in osteoarthritis patients

Bijoy Deb; Bhuvanesh Gobaloussamy; Sakthibalan Murugesan; Gayathri Sivakumar

doi:10.18203/issn.2455-4510.IntJResOrthop20241962

Authors

Bijoy Deb Ki3 Private Limited, Chennai, Tamil Nadu, India
Bhuvanesh Gobaloussamy Sri Ortho Care Clinic, Pondicherry, India
Sakthibalan Murugesan Thirumalai Medical Centre, Pondicherry, India
Gayathri Sivakumar Ki3 Private Limited, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20241962

Keywords:

OA, Collashot C2 plus capsule, ESR, C-telopeptide, Pain VAS

Abstract

Background: Osteoarthritis (OA), the most prevalent joint disease, is marked by chronic joint pain and debilitating symptoms. Many drugs are available in the market for treating osteo arthritis symptoms but there is still need for drugs with least adverse effects. So, in this study, an attempt has been done with Collashot C2 plus capsule, a nutraceutical for treating OA symptoms.

Methods: This is an outcome, quasi-experimental study where patients with OA were included. Patients were given capsule Collashot C2 plus daily for 3 months. A total of 30 male and female patients were included in the study. Changes from baseline to 12 weeks in knee pain intensity measured by pain visual analogue scale (VAS) and in Western Ontario and McMaster universities OA index (WOMAC) pain subscale, laboratory parameters, participant's global assessment of improvement of OA were assessed. Adverse drug reactions were also observed during the study period.

Results: There was a statistically significant improvement in the VAS pain scale, WOMAC pain score and in participant's global assessment of improvement of OA at week 4, week 8, and week 12 compared to baseline (p<0.001) was observed.

Conclusions: Collashot C2 plus capsule has proved to be very safe and effective in the management of OA Participants by reducing inflammation, providing adequate pain relief without causing any major side effects.

Metrics

Metrics Loading ...

References

Abhishek J, Kiran G, Partha H, Ramesh H. Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana. J Prim Care Spec. 2021;10(1):354-60.

Primorac D, Molnar V, Matisic V, Hudetz D, Jelec Z, Rod E, et al. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies' Guidelines. Pharmaceuticals (Basel). 2021;14(3):205.

Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4(4):217-43.

Rosemann T, Wensing M, Joest K, Backenstrass M, Mahler C, Szecsenyi J. Problems and needs for improving primary care of osteoarthritis patients: the views of patients, general practitioners and practice nurses. BMC Musculoskelet Disord. 2006;7(1):48.

DaCosta BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321.

Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):100-16.

Geusens P, Pavelka K, Rovensky J, Vanhoof J, Demeester N, Calomme M, et al. A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. Musculoskelet Disord. 2017;18(1):2.

Wang Z, Jones G, Winzenberg T, Cai G, Laslett LL, Aitken D, et al. Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis: A Randomized Trial. Ann Intern Med. 2020;173(11):861-9.

Siddiqui MZ. Boswellia serrata, a potential anti-inflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-61.

Luo C, Su W, Song Y, Srivastava S. Efficacy and safety of native type II collagen in modulating knee osteoarthritis symptoms: a randomised, double-blind, placebo-controlled trial. J Exp Orthop. 2022;9(1):123.

Batiha GE, Wasef L, Teibo JO, Shaheen HM, Zakariya AM, Akinfe OA, et al. Commiphora myrrh: a phytochemical and pharmacological update. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(3):405-20.

Prabhoo R. Choline-Stabilized Orthosilicic Acid and Bone Health. Curr Med Issues. 2020;18(4):312-6.

Wang Z, Jones G, Winzenberg T, Guoqi C, Laura LL, Dawn A, et al. Effectiveness of Curcuma longa extract for the treatment of symptoms and effusion–synovitis of knee osteoarthritis: a randomized trial. Ann Intern Med. 2020;173(11):861-9.

Hsiao AF, Lien Y, Tzeng IF, Lieu CT, Chou SH, Horng YS. The efficacy of high- and low-dose curcumin in knee osteoarthritis: A systematic review and meta-analysis. Complementary Therapies in Med. 2021;63:102775.

Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):225.

Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101.

Cicero AF, Girolimetto N, Bentivenga C, Grandi E, Fogacci F, Borghi C. Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis,A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Diseases. 2020;8(3):26.